These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3052464)

  • 1. Validation of biotechnological production processes.
    Werner RG; Langlouis-Gau H; Walz F; Allgaier H; Hoffmann H
    Arzneimittelforschung; 1988 Jun; 38(6):855-62. PubMed ID: 3052464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometric methodologies for the analysis of biotechnologically produced protein pharmaceuticals.
    Malorni A
    Farmaco; 1992 May; 47(5 Suppl):723-40. PubMed ID: 1524622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meeting the regulatory requirements for pharmaceutical production of recombinant DNA derived products.
    Werner RG; Langlouis-Gau H
    Arzneimittelforschung; 1989 Jan; 39(1):108-11. PubMed ID: 2719737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical considerations in the development of protein purification processes.
    Anicetti V; Hancock WS
    Bioprocess Technol; 1994; 18():11-36. PubMed ID: 7764169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency and stability of recombinant fermentations.
    Wiebe ME; Builder SE
    Dev Biol Stand; 1994; 83():45-54. PubMed ID: 7883099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of fermentation processes.
    Lubiniecki AS; Gardner AR; Smith TM; Wang WK; McAllister PR; Federici MM
    Dev Biol (Basel); 2003; 113():37-44; discussion 111-2. PubMed ID: 14620850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upflow anaerobic sludge blanket reactor--a review.
    Bal AS; Dhagat NN
    Indian J Environ Health; 2001 Apr; 43(2):1-82. PubMed ID: 12397675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preparation and validation of stock cultures of mammalian cells.
    Facklam TJ; Geyer S
    Bioprocess Technol; 1991; 13():54-85. PubMed ID: 1367151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical strategies for the determination of protein modifications.
    Janis LJ; Davis GC
    Dev Biol Stand; 1994; 83():135-42. PubMed ID: 7883087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic stability of rDNA production systems, a case report.
    Chiu YY
    Dev Biol Stand; 1994; 83():93-7. PubMed ID: 7883104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality assessment of recombinant proteins produced in plants.
    Medrano G; Dolan MC; Condori J; Radin DN; Cramer CL
    Methods Mol Biol; 2012; 824():535-64. PubMed ID: 22160919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality control of protein drugs.
    Bachmayer H
    Arzneimittelforschung; 1988 Apr; 38(4):590-1. PubMed ID: 3401274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of recombinant DNA produced pharmaceuticals by a combination of process validation and final product specifications.
    Jones AJ; O'Connor JV
    Dev Biol Stand; 1985; 59():175-80. PubMed ID: 4007276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Industry perspective on the validation of column-based separation processes for the purification of proteins. Parenteral Drug Association.
    J Parenter Sci Technol; 1992; 46(3):87-97. PubMed ID: 1522447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raw material considerations.
    Lubiniecki AS; Shadle PJ
    Dev Biol Stand; 1997; 91():65-72. PubMed ID: 9413684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of recombinant proteins in suspension-cultured plant cells.
    Plasson C; Michel R; Lienard D; Saint-Jore-Dupas C; Sourrouille C; de March GG; Gomord V
    Methods Mol Biol; 2009; 483():145-61. PubMed ID: 19183898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring manufacturing process yields, purity and stability of structural variants of PEGylated staphylokinase mutant SY161 by quantitative reverse-phase chromatography.
    Johnson C; Royal M; Moreadith R; Bedu-Addo F; Advant S; Wan M; Conn G
    Biomed Chromatogr; 2003 Jul; 17(5):335-44. PubMed ID: 12884399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cleaning validation of the prefermentation-fermentation group for production of biomedical products].
    Lencioni E; Mecatti F; Travagli V; Valeri A
    Boll Chim Farm; 2000; 139(1):8-13. PubMed ID: 10829546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.